Abstract:Pancreatic cancer (PDAC) is a lethal disease in part because tumor cells exist in distinct transcriptional states (e.g. basal/mesenchymal v.s. classical/epithelial) with unique phenotypic properties that contribute to tumor growth and treatment resistance. Two major mechanisms have been suggested for treatment evasion: (1) the intrinsic resistance of an existing state to a therapy regimen and (2) plasticity of therapy-sensitive states to adopt more resistant states. The relative contribution of these mechanisms to treatment resistance is still poorly understood. Historically, measurement of plasticity in both human patients and mouse models has involved one of three principles: (1) observing a redistribution of cell states in tissue across timepoints or conditions; (2) identifying cells that have genomic, epigenetic or proteomic features of more than one state (mixed states); and (3) performing single-cell cloning of cells and observing the cell states adopted by clonal progeny. While these approaches are observationally consistent with the notion of plasticity, they either fail to definitively prove the existence of plasticity, are restricted in measurements of plasticity outside of native tissues or are unable to quantify the role of plasticity in treatment resistance. Amongst the most well described forms of plasticity in human development and cancer is epithelial-mesenchymal plasticity (EMP), which includes epithelial to mesenchymal transition (EMT) and mesenchymal to epithelial transition (MET). To better understand and quantify the role of EMP in driving treatment resistance of human PDAC, we have developed single-cell multiomic, functional genomic and computational methods applied to patient-derived models and clinical biopsies. We first profiled twelve patient-derived PDAC cell lines by single-cell RNA-seq (scSeq) and learned convergent epithelial and mesenchymal gene programs that were consistent with programs observed in patient samples. We next performed lineage tracing experiments in three PDAC cell lines using an expressed lentiviral barcoding system (ClonMapper). By performing scSeq on these barcoded lines at weekly timepoints over four weeks, we proved the presence of EMP by showing a single cell can produce progeny in both epithelial and mesenchymal states. We next developed a generative probabilistic model of our lineage tracing data. This demonstrated that clones (cells sharing a barcode) had different transition matrices (different EMT and MET rates), thus suggesting each clone has a distinct level of plasticity. Having established this, we focused on identifying genes that might explain the differing plasticity properties of clones. Using elastic net regression we identified 50 transcription factors (TFs) whose expression significantly explained the propensity for EMP over time across clonal populations. Among these were were several known EMP TFs (Zeb1 and Gata6), understudied TFs (Elf3, Sox2, Sox4, Klf3, Klf5 and Atf4) and novel TFs (Meis2, Meis3, FoxA1 and the interferon regulatory factors Irf6, Irf7 and Irf9). Using single-cell multiomics (paired scSeq and single-cell ATAC-seq) on our barcoded population, we found that 9 of the 50 predicted TFs, including Elf3, had differential accessibility between clones with different plasticity properties, suggesting a role for epigenetic regulation of these TFs in facilitating EMP. Importantly, we leveraged our multiomic data to infer gene regulatory networks influenced by these TFs and found an enrichment of binding motifs for these TFs in enhancer regions of genes in epithelial and mesenchymal programs. To study the role of these predicted TFs in modulating EMP, we developed a CRISPRi system that enabled gene perturbations alongside lineage tracing. We performed a CRISPRi perturb-seq experiment (CRISPR perturbation with scSeq readouts), perturbing the 50 predicted TFs above and 10 control genes, and collected 1.5 million single-cell transcriptomic profiles, in addition to two other CRISPR KO perturb-seq experiments. We performed a negative binomial regression to estimate effect sizes of guide RNAs on all genes. 60% of our guides had significant perturbation effects on their target gene. We subsequently found Klf3 as an important regulator of PDAC proliferation independent of cell state. Importantly, we found that knockdown (KD) of several factors, such has Grhl2 and FoxA1, bias towards mesenchymal cell states, whereas KD of others such as Batf2, Snai1, Rel, Zeb1, Nr2f1 and Sox4 led to a bias towards epithelial cell states. Interestingly, KD of several TFs influenced transition properties of cells by decreasing rates of EMT and MET across barcodes without biasing the overall clonal distribution towards a single cell state. This suggests a role for these TFs in enabling plasticity and facilitating state transitions. To study the effect of plasticity in treatment res -Abstract Truncated-

Abstract 423: Cell state-specific genomics to define plasticity along the epithelial-mesenchymal transitioncontinuum

Abstract 6940: The transcriptional and epigenetic regulation of epithelial-mesenchymal plasticity in patient-derived pancreatic cancer cell lines

Abstract A069: The molecular landscape of injury-induced mammary epithelial cell fate switching

Abstract LB223: The molecular landscape of injury-induced mammary epithelial cell fate switching

Abstract IA015: Combined single cell atlasing and organoid modeling reveal progressive plasticity during human colorectal cancer metastasis

Reconstruction of single cell lineage trajectories and identification of diversity in fates during the epithelial-to-mesenchymal transition

Isolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer

Abstract 2756: Single cell analysis reveals treatment response-associated plastic cell state and lineage switching in aggressive variant prostate cancer

Abstract 6626: Functional and molecular interrogation of a high-plasticity cell state in lung cancer

Abstract NG08: Dissecting and quantifying pancreatic cancer plasticity using single-cell multiomics, lineage tracing and functional genomics reveals novel mediators of therapy resistance

Abstract 7042: Enhancing TCR T cell function in solid tumors through in vivo combinatorial screens and single-cell analysis

Abstract 2465: Gene Expression, Phenotypic and Karyotypic Analyses of Stepwise Prostate Carcinogenesisin Vitro

Abstract 5421: Characterizing functional cell migration states with highly multiplexed immunofluorescence imaging

Abstract LB233: Single-cell transcriptional analysis of embryonic melanoblasts pinpoints embryonic cell states that underlie targeted therapy and immune checkpoint blockade resistance

Abstract 5398: Single-cell transcriptomic analysis of partial endothelial-to-mesenchymal transition in sprouting angiogenesis

Abstract 2641: Transcriptional reprogramming of Ewing tumors: gains and losses noted when utilizing immunocompetent in vivo models

Abstract 1467: A novel screening model to identify EWS::FLI1 regulators and their consequences on Ewing sarcoma plasticity

Abstract 1225: the existence, characteristics and underlying regulators of spontaneous epithelial-mesenchymal transition from a monophasic metaplastic squamous carcinoma patient-derived cancer cell model

Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing

Abstract 6284: Multimoics reveal aberrant pathways and regulation of castration resistant and metastatic prostate cancer

Abstract 211: Applying cellular thermal shift assays to uncover novel regulators of epithelial to mesenchymal transition in triple negative breast cancer